• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Relax…Who Are We Going To Buy?

Quote








Some potential targets

1) Companies with assets that treat biomarkers but not underlying disease. These can be added to the portfolio of sod1, adu, and probably ban2401. Unique biogen expertise.

2) Companies with has been assets with marginal to failing results in phase 1 or 2. The assets just need someone who has nothing better to do and can try harder.

3) Companies available for cheap because they only have phase 1 assets with low likelihood of success. These can join Biogens stable of little chance to succeed molecules. And Lingo can come back into the mix to join the fun.

Lets be honest. Buying power looks to be pretty diminished at this point given stock and cash positions. How about another stock buyback.
 




Top Bottom
Back
Quote